The purpose of this study is to evaluate whether extended prophylaxis with oral betrixaban can prevent blood clots in the leg and lung that sometime occur in patients hospitalized for an acute medical illness and to compare these results with standard of care enoxaparin. The safety of betrixaban will also be studied.
Betrixaban 80 mg PO once daily (QD) for 35 day + 7 days. Enoxaparin Placebo: Once daily, 6-14 days
Enoxaparin 40 mg subcutaneous (SC) QD for 10 ± 4 days. Betrixaban Placebo: once daily, 35 days
Buenos Aires, Argentina
Buenos Aires, Argentina
Coronel Suarez, Buenos Aires, Argentina
Corrientes, Argentina
Córdoba, Argentina
El Talar, Argentina
Rosario, Santa Fe, Argentina
San Miguel de Tucumán, Argentina